Loading clinical trials...
Loading clinical trials...
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
Conditions
Interventions
Elotuzumab
Pomalidomide
+2 more
Locations
6
United States
California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, United States
Robert A. Moss, MD, FACP, Inc
Fountain Valley, California, United States
Pacific Cancer Care
Monterey, California, United States
James Berenson, MD, Inc
West Hollywood, California, United States
Millennium Oncology Research Clinic
Pembroke Pines, Florida, United States
Regional Cancer Care Associates MD LLC
Bethesda, Maryland, United States
Start Date
March 13, 2017
Primary Completion Date
October 25, 2019
Completion Date
January 23, 2020
Last Updated
March 31, 2022
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06383143
NCT06870760
Lead Sponsor
Oncotherapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions